More than 75% of the U.S. population lives in states that have legalized cannabis for adult and/or medical use.
Pursuant to a 2022 directive from President Joe Biden, a 2023 recommendation of the U.S. Department of Health and Human Services, and a scientific review released in January supporting the HHS's recommendation, the U.S. Drug Enforcement Administration is now evaluating whether to reclassify cannabis as a Schedule III drug.
USA, Healthcare & Life Sciences, Insolvency & Restructuring, Product Regulation & Liability, Duane Morris LLP, Cannabis, US Department of Justice, US Department of Health and Human Services